PMR Adverse Events, Elusive Efficacy Endpoints Cited In Panel Rejection
This article was originally published in The Gray Sheet
Executive Summary
The reliance on hospitalization for angina as a safety endpoint in the clinical trials of CardioGenesis' Eclipse PMR (percutaneous myocardial revascularization) device masked the rate of significant adverse events related to the procedure, according to FDA's Circulatory System Devices Panel.
You may also be interested in...
CardioGenesis PMR Not Approvable; Firm May Seek Strategic Investor/Partner
CardioGenesis may look for a strategic partner to support its continued pursuit of approval for laser percutaneous myocardial revascularization (PMR)
CardioGenesis PMR Not Approvable; Firm May Seek Strategic Investor/Partner
CardioGenesis may look for a strategic partner to support its continued pursuit of approval for laser percutaneous myocardial revascularization (PMR)
Zoll Defibrillator Sales Growth, Upcoming Public AED Entry Buoy Stock In July
Zoll Medical's upcoming entry into the public access automated external defibrillator (AED) market, coupled with revived sales growth in its third fiscal quarter, helped the firm's stock jump ahead 33% in July. The issue closed at $36.45, up $9 for the month.